New and old treatment modalities in primary myelofibrosis

Francisco Cervantes, Ruben Mesa, Giovanni Barosi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The treatment of primary myelofibrosis (PMF) remains essentially palliative. Conventional modalities include a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and splenectomy in selected patients. These therapeutic modalities improve the patients quality of life but have no impact on survival. Newer therapies for PMF are currently being used. Antiangiogenic and immunomodulatory drugs such as thalidomide and lenalidomide are associated with frequent side effects but have shown certain efficacy, especially for the anemia and thrombocytopenia. The association of low-dose thalidomide with prednisone has better tolerability, and it is also effective. Tyrosine kinase inhibitors such as imatinib have also been used, but their efficacy is limited. Tipifarnib, a farnesyltransferase inhibitor, has shown certain effects in the anemia. Allogeneic stem cell transplantation (SCT) is the only curative therapy for PMF. Its standard modality has an associated mortality of 30%, and it is indicated in younger patients with high-risk disease or disease resistant to conventional treatment. Reduced-intensity conditioning allogeneic SCT is associated with low mortality while maintaining a curative potential, and until longer follow-up is available, it can be used in patients aged 45ĝ€"70 years old with high- or intermediate-risk myelofibrosis or myelofibrosis resistant to treatment. Autologous SCT is a palliative measure that can be considered in patients with resistant disease, who lack a suitable donor. Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested.

Original languageEnglish (US)
Pages (from-to)377-383
Number of pages7
JournalCancer Journal
Volume13
Issue number6
DOIs
StatePublished - Nov 2007

Fingerprint

Primary Myelofibrosis
Stem Cell Transplantation
Anemia
Thalidomide
tipifarnib
Therapeutics
Pharmaceutical Preparations
Farnesyltranstransferase
Proteasome Inhibitors
Hydroxyurea
Mortality
Splenectomy
Erythropoietin
Prednisone
Thrombocytopenia
Protein-Tyrosine Kinases
Androgens
Quality of Life
Tissue Donors
Survival

Keywords

  • Idiopathic myelofibrosis
  • Immunomodulatory drugs
  • Myelofibrosis with myeloid metaplasia
  • Primary myelofibrosis
  • Stem cell transplantation
  • Treatment
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

New and old treatment modalities in primary myelofibrosis. / Cervantes, Francisco; Mesa, Ruben; Barosi, Giovanni.

In: Cancer Journal, Vol. 13, No. 6, 11.2007, p. 377-383.

Research output: Contribution to journalArticle

Cervantes, Francisco ; Mesa, Ruben ; Barosi, Giovanni. / New and old treatment modalities in primary myelofibrosis. In: Cancer Journal. 2007 ; Vol. 13, No. 6. pp. 377-383.
@article{4c9ab7267c6d478b9538073647610706,
title = "New and old treatment modalities in primary myelofibrosis",
abstract = "The treatment of primary myelofibrosis (PMF) remains essentially palliative. Conventional modalities include a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and splenectomy in selected patients. These therapeutic modalities improve the patients quality of life but have no impact on survival. Newer therapies for PMF are currently being used. Antiangiogenic and immunomodulatory drugs such as thalidomide and lenalidomide are associated with frequent side effects but have shown certain efficacy, especially for the anemia and thrombocytopenia. The association of low-dose thalidomide with prednisone has better tolerability, and it is also effective. Tyrosine kinase inhibitors such as imatinib have also been used, but their efficacy is limited. Tipifarnib, a farnesyltransferase inhibitor, has shown certain effects in the anemia. Allogeneic stem cell transplantation (SCT) is the only curative therapy for PMF. Its standard modality has an associated mortality of 30{\%}, and it is indicated in younger patients with high-risk disease or disease resistant to conventional treatment. Reduced-intensity conditioning allogeneic SCT is associated with low mortality while maintaining a curative potential, and until longer follow-up is available, it can be used in patients aged 45ĝ€{"}70 years old with high- or intermediate-risk myelofibrosis or myelofibrosis resistant to treatment. Autologous SCT is a palliative measure that can be considered in patients with resistant disease, who lack a suitable donor. Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested.",
keywords = "Idiopathic myelofibrosis, Immunomodulatory drugs, Myelofibrosis with myeloid metaplasia, Primary myelofibrosis, Stem cell transplantation, Treatment, Tyrosine kinase inhibitors",
author = "Francisco Cervantes and Ruben Mesa and Giovanni Barosi",
year = "2007",
month = "11",
doi = "10.1097/PPO.0b013e31815a7c0a",
language = "English (US)",
volume = "13",
pages = "377--383",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - New and old treatment modalities in primary myelofibrosis

AU - Cervantes, Francisco

AU - Mesa, Ruben

AU - Barosi, Giovanni

PY - 2007/11

Y1 - 2007/11

N2 - The treatment of primary myelofibrosis (PMF) remains essentially palliative. Conventional modalities include a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and splenectomy in selected patients. These therapeutic modalities improve the patients quality of life but have no impact on survival. Newer therapies for PMF are currently being used. Antiangiogenic and immunomodulatory drugs such as thalidomide and lenalidomide are associated with frequent side effects but have shown certain efficacy, especially for the anemia and thrombocytopenia. The association of low-dose thalidomide with prednisone has better tolerability, and it is also effective. Tyrosine kinase inhibitors such as imatinib have also been used, but their efficacy is limited. Tipifarnib, a farnesyltransferase inhibitor, has shown certain effects in the anemia. Allogeneic stem cell transplantation (SCT) is the only curative therapy for PMF. Its standard modality has an associated mortality of 30%, and it is indicated in younger patients with high-risk disease or disease resistant to conventional treatment. Reduced-intensity conditioning allogeneic SCT is associated with low mortality while maintaining a curative potential, and until longer follow-up is available, it can be used in patients aged 45ĝ€"70 years old with high- or intermediate-risk myelofibrosis or myelofibrosis resistant to treatment. Autologous SCT is a palliative measure that can be considered in patients with resistant disease, who lack a suitable donor. Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested.

AB - The treatment of primary myelofibrosis (PMF) remains essentially palliative. Conventional modalities include a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and splenectomy in selected patients. These therapeutic modalities improve the patients quality of life but have no impact on survival. Newer therapies for PMF are currently being used. Antiangiogenic and immunomodulatory drugs such as thalidomide and lenalidomide are associated with frequent side effects but have shown certain efficacy, especially for the anemia and thrombocytopenia. The association of low-dose thalidomide with prednisone has better tolerability, and it is also effective. Tyrosine kinase inhibitors such as imatinib have also been used, but their efficacy is limited. Tipifarnib, a farnesyltransferase inhibitor, has shown certain effects in the anemia. Allogeneic stem cell transplantation (SCT) is the only curative therapy for PMF. Its standard modality has an associated mortality of 30%, and it is indicated in younger patients with high-risk disease or disease resistant to conventional treatment. Reduced-intensity conditioning allogeneic SCT is associated with low mortality while maintaining a curative potential, and until longer follow-up is available, it can be used in patients aged 45ĝ€"70 years old with high- or intermediate-risk myelofibrosis or myelofibrosis resistant to treatment. Autologous SCT is a palliative measure that can be considered in patients with resistant disease, who lack a suitable donor. Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested.

KW - Idiopathic myelofibrosis

KW - Immunomodulatory drugs

KW - Myelofibrosis with myeloid metaplasia

KW - Primary myelofibrosis

KW - Stem cell transplantation

KW - Treatment

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=39749167036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749167036&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31815a7c0a

DO - 10.1097/PPO.0b013e31815a7c0a

M3 - Article

C2 - 18032975

AN - SCOPUS:39749167036

VL - 13

SP - 377

EP - 383

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 6

ER -